

Resource Summary Report

Generated by RRID on Sep 1, 2026

NoGFP-CD16.NK92

RRID:CVCL_V429

Type: Cell Line

Proper Citation

ATCC Cat# PTA-6967, RRID:CVCL_V429

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_V429

Proper Citation: ATCC Cat# PTA-6967, RRID:CVCL_V429

Description: Cell line NoGFP-CD16.NK92 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Comments: Population: Caucasian., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NoGFP-CD16.NK92

Cross References: ATCC:PTA-6967, Wikidata:Q54930889

ID: CVCL_V429

Vendor: ATCC

Catalog Number: PTA-6967

Hierarchy: cvcl_2142

Record Creation Time: 20250130T072538+0000

Record Last Update: 20260830T001655+0000

Ratings and Alerts

No rating or validation information has been found for NoGFP-CD16.NK92.

No alerts have been found for NoGFP-CD16.NK92.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yang Z, et al. (2026) Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Cell reports. Medicine, 7(2), 102613.

Miles JR, et al. (2025) ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria. Cell reports, 44(12), 116653.

Gelderloos AT, et al. (2024) Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults. Immunity & ageing : I & A, 21(1), 63.

Gelderloos AT, et al. (2024) Primary SARS-CoV-2 infection in children and adults results in similar Fc-mediated antibody effector function patterns. Clinical & translational immunology, 13(8), e1521.

Bates TA, et al. (2022) BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell reports, 41(4), 111544.

Xiong Q, et al. (2022) A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity. Oncoimmunology, 11(1), 2127282.